http://www.radiuscorporation.com
Radius Technology Corporation provides computer hardware and software solutions designed to streamline and accelerate the flow of critical information during everyday processes. Advances in hardware technology occur rapidly which subsequently leaves many agencies and companies behind in the technology curve. Radius Technology Corporation strives to keep companies on the cutting edge of technology. GIS Mapping data can be collected with very precise accuracy, updated daily, and synchronized company-wide for faster operations and efficiency.
Chrysalis BioTechnology, Inc. is a biopharmaceutical company developing new therapeutics to accelerate the healing of hard and soft tissue. The Company's lead product, Chrysalin®, is currently in Phase III human clinical for bone fracture healing, and Phase II trials for chronic diabetic ulcers.
In January of 2002, ARC decided to focus its research & development efforts on loading novel therapeutics into medical devices in order to significantly increase the effectiveness of these devices. This decision was based on the potential market size and the existing core expertise of the Company. In October, 2003, ARC entered into an exclusive worldwide license agreement with UBC for the therapeutic uses of fucans, including the ARCADÔ Instillate technology. Since July 2002, ARC has successfully loaded novel therapeutic agents into films, gels and instillates and completed proof of principle efficacy and safety studies in several preclinical models of surgical adhesions. For the ARCAD Instillate lead product candidate ARC has completed preclinical animal efficacy studies, pilot animal safety studies, and pilot stability studies.
Synairgen plc is the holding company for Synairgen Research Limited, a drug discovery and development company focused on developing therapies which address the causes, rather than the symptoms, of respiratory disease. As at June 30, 2008, the Company’s programmes were IFN-beta, protein, collaboration and other research programmes. IFN-beta is for the treatment or prevention of exacerbations (attacks) of asthma and chronic obstructive pulmonary disease (COPD) caused by the common cold. (Source: ARS)
FemmePharma, Inc. was formed by Gerianne Tringali-DiPiano in 1996 to target identifiable unmet needs within the women's healthcare pharmaceutical market. The Company has a number of drugs in development based on its PARDEL technology. FemmePharma, Inc. is devoted to developing safe and effective drugs that minimize or eliminate unpleasant side effects associated with many medications by designing them in a manner that is specifically suited to a women's physiology, with an eye toward the changing needs of women throughout their lives. The Company has a number of drugs in development based on its proprietary technologies including new therapeutic options for fibrocystic breast disease.
Prana Biotechnology Limited is a development stage company at an early stage in the development of its pharmaceutical products that are designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. Other potential applications for the Company’s therapies include Huntington’s disease, Parkinson’s disease, certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease) and age-related cataracts. The Company has two wholly owned subsidiaries, Prana Biotechnology Inc. and Prana Biotechnology UK Limited. In May 2008, the Company announced that several promising candidate lead metal protein attenuating compound were demonstrating promising characteristics in animal models of Parkinson’s disease. (Source: 20-F)
IBEX Technologies, Inc. (IBEX) is a biopharmaceutical company engaged in the production and sale of enzymes for use as reagents in hemostasis monitoring devices, and of arthritis diagnostic kits for pharmaceutical research. It is principally engaged in the production and sale of diagnostic products. IBEX sells its products, enzymes and diagnostic kits, either directly or through distributors. It has focused on the isolation, characterization and high-level expression of glycosaminoglycan GAG lyase enzymes derived from Flavobacterium heparinum, a non-pathogenic soil organism. IBEX has developed a Flavobacterium heparinum production system. This system allows the production of recombinant forms of these GAG lyases. IBEX produces heparinase I, heparinase II, heparinase III, chondroitinase AC and chondroitinase B. (Source: ARS)
Endovasc, Inc. is a business development company focused on drug development in the areas of cardiovascular and metabolic medicine. The Company’s licenses and patents describe technological advancements related to liposomes, stent coatings, and biodegradable/resorbable prostheses (stents) for the treatment of vascular dysfunction and heart disease. The Company’s products include Liprostin and PROStent.
Dimethaid Research Inc. is a fully integrated pharmaceutical company headquartered in Canada with subsidiaries in Europe, Asia and the Caribbean. The company is focused on the commercialization of therapeutics designed to produce minimal side effects. Dimethaid is engaged in all stages of pharmaceutical development, from R&D, through clinical and regulatory filing, to full-scale manufacturing and marketing. Dimethaid Research Inc. trades on the Toronto Stock Exchange under the symbol DMX.
At ILEX, we continue to research and acquire compounds with unique mechanisms of action, targeting novel receptors. We are focused on building a portfolio of oncology compounds that are different than those already available to patients and that provide new hope with effective and safe treatments for cancer. The ILEX history of drug development remains the core competency of the company and is now focused on ILEX's own pipeline. In addition to its strong scientific and clinical staff, ILEX has a knowledgeable management team with extensive pharmaceutical industry experience. ILEX is building a product-driven biopharmaceutical company focused primarily in oncology. ILEX has a marketed product, CAMPATH® (alemtuzumab) in the United States and MABCAMPATH® in the European Union, and is advancing an innovative and diversified pipeline of compounds.
Vasogen Inc. (Vasogen) is a biotechnology company focused on the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company’s lead product, Celacade, is designed to activate the immune response to apoptosis, a physiological process that regulates inflammation. Celacade has received European regulatory approval for chronic heart failure and is being marketed in the European Union by Ferrer Internacional S.A. (Ferrer). Celacade is in late-stage clinical development for the treatment of chronic heart failure in the United States. Vasogen is also developing a class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this class. (Source: 20-F)
Callisto Pharmaceuticals, Inc. (Callisto) is a biopharmaceutical company focused primarily on the development of drugs to treat neuroendocrine cancer (including advanced carcinoid cancer), acute leukemia and gastrointestinal disorders and diseases. The Company’s lead drug candidate, Atiprimod, is being developed as a treatment for carcinoid cancer. Callisto’s second drug candidate, L-Annamycin, is being developed to treat relapsed acute leukemia. A third drug candidate, SP-304 (guanilib), is being developed as a treatment for gastrointestinal disorders. (Source: 10-K)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory